Adaptimmune Therapeutics PLC - Company Profile (NASDAQ:ADAP)

About Adaptimmune Therapeutics PLC -

Adaptimmune Therapeutics PLC - logoAdaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company's TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADAP
  • CUSIP:
Key Metrics:
  • Previous Close: $7.10
  • 50 Day Moving Average: $7.77
  • 200 Day Moving Average: $8.63
  • 52-Week Range: $6.19 - $14.78
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.87
  • P/E Growth: 0.39
  • Market Cap: $506.82M
  • Outstanding Shares: 70,785,000
  • Beta: 1.18
Additional Links:
Companies Related to Adaptimmune Therapeutics PLC -:

Analyst Ratings

Consensus Ratings for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.00 (153.52% upside)

Analysts' Ratings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Show:
DateFirmActionRatingPrice TargetDetails
4/24/2016Leerink SwannReiterated RatingBuyView Rating Details
2/27/2016Deutsche Bank AGInitiated CoverageBuyView Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$15.00View Rating Details
12/22/2015SunTrust Banks Inc.Initiated CoverageBuy$16.00View Rating Details
10/15/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
6/1/2015GuggenheimInitiated CoverageBuy$25.00View Rating Details
6/1/2015Bank of America Corp.Initiated CoverageNeutral$17.00View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016        
8/8/2016Q2($0.21)($0.05)ViewListenView Earnings Details
5/12/2016Q1($0.19)($0.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-1.21 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.20)($0.16)($0.18)
Q2 20163($0.26)($0.19)($0.22)
Q3 20162($0.20)($0.18)($0.19)
Q4 20162($0.26)($0.24)($0.25)
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.31)($0.31)($0.31)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/24/2016Orbimed Advisors LlcDirectorBuy1,712,400$10.42$17,843,208.00View SEC Filing  
5/19/2016Charles Elliott SigalDirectorBuy15,000$1.56$23,400.00View SEC Filing  
5/18/2016Charles Elliott SigalDirectorBuy45,000$1.53$68,850.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
DateHeadline
News IconAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Company In Focus: Analysts & Crowd Weigh in - Post News (NASDAQ:ADAP)
www.kentuckypostnews.com - August 25 at 8:04 AM
investornewswire.com logoAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - August 24 at 3:18 PM
investornewswire.com logoWill Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Hit $16 Price Target? - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - August 17 at 8:49 PM
finance.yahoo.com logoEdited Transcript of ADAP earnings conference call or presentation 8-Aug-16 12:00pm GMT (NASDAQ:ADAP)
finance.yahoo.com - August 17 at 3:20 PM
prnewswire.com logoT-Cell Immunotherapy for Cancer - Pipeline Analysis (NASDAQ:ADAP)
www.prnewswire.com - August 16 at 8:37 PM
finance.yahoo.com logoADAPTIMMUNE THERAPEUTICS PLC Financials (NASDAQ:ADAP)
finance.yahoo.com - August 16 at 3:19 PM
biz.yahoo.com logoADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and (NASDAQ:ADAP)
biz.yahoo.com - August 12 at 8:40 PM
benzinga.com logoA Handful of Biotech Stocks Plunge After Disappointing Results - Benzinga (NASDAQ:ADAP)
www.benzinga.com - August 9 at 12:03 PM
reuters.com logoBRIEF-Adaptimmune Q2 net loss per diluted ordinary share $0.05 (NASDAQ:ADAP)
www.reuters.com - August 8 at 8:45 PM
4-traders.com logoADAPTIMMUNE THERAPEUTICS PLC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:ADAP)
www.4-traders.com - August 8 at 8:45 PM
biz.yahoo.com logoAdaptimmune Therapeutics PLC Earnings Call (Q2 2016) (NASDAQ:ADAP)
biz.yahoo.com - August 8 at 8:45 PM
streetinsider.com logoForm 8-K Adaptimmune Therapeutics For: Aug 08 - StreetInsider.com (NASDAQ:ADAP)
www.streetinsider.com - August 8 at 8:05 AM
biz.yahoo.com logoAdaptimmune Therapeutics PLC Earnings Call scheduled for 8:00 am ET today (NASDAQ:ADAP)
biz.yahoo.com - August 8 at 8:05 AM
streetinsider.com logoAdaptimmune (ADAP) Receives Partial FDA Clinical Hold on NY-ESO SPEAR Study in MRCLS (NASDAQ:ADAP)
www.streetinsider.com - August 5 at 3:16 PM
marketexclusive.com logoA Guess At What’s Behind The Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Clinical Hold (NASDAQ:ADAP)
marketexclusive.com - August 5 at 3:16 PM
marketexclusive.com logoA Guess At What's Behind The Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Clinical Hold - Market Exclusive (NASDAQ:ADAP)
marketexclusive.com - August 4 at 3:19 PM
investornewswire.com logoStrong Sell Calls For Adaptimmune Therapeutics PLC - ADR ... - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - August 4 at 11:49 AM
biz.yahoo.com logoADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ADAP)
biz.yahoo.com - August 4 at 11:49 AM
nasdaq.com logoAdaptimmune Reports Partial Clinical Hold On NY-ESO SPEAR T-cell Therapy Study (NASDAQ:ADAP)
www.nasdaq.com - August 3 at 8:56 PM
nasdaq.com logoAdaptimmune to Report Second Quarter 2016 Financial Results on August 8, 2016 - Nasdaq (NASDAQ:ADAP)
www.nasdaq.com - August 2 at 8:56 PM
publicnow.com logoAdaptimmune to Report Second Quarter 2016 Financial Results on August 8, 2016 (NASDAQ:ADAP)
www.publicnow.com - August 2 at 3:18 PM
finance.yahoo.com logoADAP: a Biotech Stock Using T-Cell Immunotherapy to Treat Cancer (NASDAQ:ADAP)
finance.yahoo.com - August 2 at 8:04 AM
News IconAdaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO f. (NASDAQ:ADAP)
www.stock-world.de - July 28 at 4:16 PM
News IconAdaptimmune's NY-ESO SPEAR T-cell therapy to treat soft tissue sarcoma receives European orphan drug status (NASDAQ:ADAP)
pharmabiz.com - July 28 at 4:16 PM
globenewswire.com logoNew Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs (NASDAQ:ADAP)
globenewswire.com - July 28 at 4:16 PM
reuters.com logoBRIEF-Adaptimmune Therapeutics files for potential offering of ADS of up to $250 mln - Reuters (NASDAQ:ADAP)
www.reuters.com - July 28 at 11:55 AM
publicnow.com logoAdaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma (NASDAQ:ADAP)
www.publicnow.com - July 28 at 11:48 AM
investornewswire.com logoCan Shares Of Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Hit $23? - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - July 27 at 9:02 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Receives EC Orphan Drug Designation for NY-ESO SPEAR T-cell Therapy in STS - StreetInsider.com (NASDAQ:ADAP)
www.streetinsider.com - July 26 at 3:18 PM
publicnow.com logoAdaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma (NASDAQ:ADAP)
www.publicnow.com - July 26 at 8:18 AM
finance.yahoo.com logo8:03 am Adaptimmune Therapeutics announces that the EC has designated its NY-ESO SPEAR T-cell therapy as an orphan medicinal product for the treatment of soft tissue sarcoma (NASDAQ:ADAP)
finance.yahoo.com - July 26 at 8:03 AM
News IconStock Focus: Following Analyst Expectations on Shares of Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Engelwood Daily (NASDAQ:ADAP)
www.engelwooddaily.com - July 23 at 3:18 PM
News IconCould Adaptimmune Therapeutics PLC - ADR Lose Strenght? The Stock Increases A Lot Today - Consumer Eagle (NASDAQ:ADAP)
www.consumereagle.com - July 22 at 3:18 PM
News IconHow Analysts Feel About Adaptimmune Therapeutics PLC - ADR After Today's Huge Decline? - Consumer Eagle (NASDAQ:ADAP)
www.consumereagle.com - July 21 at 3:19 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - TGP (NASDAQ:ADAP)
telanaganapress.com - July 21 at 3:19 PM
News IconA Reversal for Adaptimmune Therapeutics PLC - ADR Is Not Near. The Stock Rises Again - Consumer Eagle (NASDAQ:ADAP)
www.consumereagle.com - July 21 at 3:19 PM
News IconAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ADAP)
www.engelwooddaily.com - July 20 at 11:26 AM
ftsenews.co.uk logoAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Updated Price Targets - FTSE News (NASDAQ:ADAP)
www.ftsenews.co.uk - July 20 at 11:26 AM
News IconAdaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) Shorts Decreased by 18.33% After Short Covering - Consumer Eagle (NASDAQ:ADAP)
www.consumereagle.com - July 19 at 9:29 AM
News IconTrading Performance and Target Watch for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Press Telegraph (NASDAQ:ADAP)
presstelegraph.com - July 18 at 8:05 AM
News IconAdaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) Short Interest Decreased By 3.51% - Consumer Eagle (NASDAQ:ADAP)
www.consumereagle.com - July 16 at 3:19 PM
News IconCrowd Rating and Earnings Recap for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Telanagana Press (NASDAQ:ADAP)
telanaganapress.com - July 14 at 3:20 PM
news.cmlviz.com logoAdaptimmune Therapeutics plc Realized Volatility Hits Extreme Level - CML News (NASDAQ:ADAP)
news.cmlviz.com - July 14 at 3:20 PM
investornewswire.com logoStrong Sell Calls For Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) At 0 - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - July 13 at 3:19 PM
News IconAnalyst Target and Average Rating Watch: Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Press Telegraph (NASDAQ:ADAP)
presstelegraph.com - July 13 at 11:24 AM
News IconAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:ADAP)
www.engelwooddaily.com - July 12 at 8:48 PM
fiscalstandard.com logoAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:ADAP)
www.fiscalstandard.com - July 10 at 8:04 AM
biz.yahoo.com logoADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:ADAP)
biz.yahoo.com - July 8 at 4:50 PM
news.cmlviz.com logoAdaptimmune Therapeutics plc Stock Momentum Hits Weakness - CML News (NASDAQ:ADAP)
news.cmlviz.com - July 7 at 8:35 PM
investornewswire.com logoAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Expected to Reach Highs Of $23 - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - July 6 at 3:19 PM

Social

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff